NF. Evaluating Anti β-2 Glycoprotein as Rapid Thromboembolic Marker Among HCV Patients in Egypt
American Journal of Life Sciences
Volume 1, Issue 1, February 2013, Pages: 1-5
Received: Feb. 2, 2013;
Published: Feb. 20, 2013
Views 3143 Downloads 151
Elkhouly EH, Tropical, Faculty of Medicine, University of Alexandria, Egypt
Morsi MG, Medical Microbiology& Immunology, Faculty of Medicine, University of Alexandria, Egypt
Hamed NA, Internal Medicine (Hematology unit), Faculty of Medicine, University of Alexandria, Egypt
Soliman AA, Internal Medicine (Hematology unit), Faculty of Medicine, University of Alexandria, Egypt
Hanafi NF, Medical Microbiology& Immunology, Faculty of Medicine, University of Alexandria, Egypt
Although antiphospholipid (APL) antibodies are still not clearly known, yet they have association with thromboembolic events associated with hepatitis C virus (HCV) infection. Moreover, high percent of HCV infections and thromboembolic risk was associated among thalassemic patients. So our aim was to screen and evaluate the significance of ACL and anti β-2 glycoprotein seroprevelance among patients receiving repeated blood transfusions, in patients with infectious diseases as chronic HCV disorders, and in healthy subjects resident in Egypt, a tropical country endemic for hepatitis and to evaluate these tests as rapid markers for early detection of thrombotic HCV infection among chronic liver disorders and cases receiving repeated blood transfusion aiming at early anticoagulant therapy.The study was carried out on 70 patients attending Tropical, Hepatology and Hematology departments in Alexandria Main University Hospital, Egypt as well as 30 healthy subjects served as controls. Group I; 35 chronic liver disorders as chronic HCV, cirrhosis and Hepatocellular carcinoma(HCC) diagnosed by clinical, ultrasound and histopathology. Group II ; 35 receiving repeated blood transfusion as thalassemia. Group III; healthy relatives –ve for HCV antibody of matched age and sex. Both markers were screened by commercial enzyme immunosorbant assays (ELISA) (Calbiotech,USA). Our results revealed that patients with chronic HCV infection had higher anticardiolipin (ACL) IgG and antibeta2GP1 IgG compared to healthy controls. (26.6%) 8 patients from group I had high ACL IgG compared to 6 patients (20%) of group II .The study also revealed that anti β-2 glycoprotein IgG was higher among Group I and II compared to controls group III. Group I was higher than group II. Three patients (10%) of group I had high antiβ2 glycoprotein1 IgG compared to 2 patients (6.6%) among group II . We can conclude that anticardiolipin (ACL)alone is not diagnostic for thrombosis & it should be accompanied with antibeta(β )2glycoprotein-1 in serum of the same patient to be considered a cause of thrombosis in chronic HCV patients. So, ACL alone can not be considered rapid marker of thrombosis in HCV positive patients. We recommend anti β2 glycoprotein as a biomarker predicting thrombotic HCV infection
NF. Evaluating Anti β-2 Glycoprotein as Rapid Thromboembolic Marker Among HCV Patients in Egypt, American Journal of Life Sciences.
Vol. 1, No. 1,
2013, pp. 1-5.
Terashi H, Uchiyama S, Hashimoto S, Miyazaki K, Tsutsumi Y& Yamazak M . Clinical characteristics of stroke patient with antiphopholipids antibodies. Cerebrovasc Dis 2005; 19: 384-390.
Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH & Hennekens CH. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002.
Ahmed E, Birgitta S, Trifunovic J, Weinehall L, Hallmans G & Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke. An incident case-referent study nested within the MONICA and Vksterbotten Cohort Project. Stroke 2000; 31: 1289-1293.
Adebajo AO, Charles P, Maini RN & Hazleman BL. Autoantibodies in malaria, tuberculosis and hepatitis B in a West African population. Clin Exp Immunol 1993; 92: 73-76.
Jakosen PH, Morris-Jones SD, Hviid L, Theander TG, Hoier-Madsen M & Bayoumi RA. Antiphospholipids antibodies in patients with Plasmodium falciparum malaria. Immunology 1993; 79: 653-657.
Arviex J, Renaudineau Y, Mane I, Perraut R, Krilis SA &Youinou P. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost 2002; 4: 599-605.
Consigny PH, Cauquelin B, Agnamey P, Comby E, Brasseur P & Ballet JJ. High prevalence of co-factor independent anticardiolipin antibodies in malaria exposed individuals. Clin Exp Immunol 2002; 127: 158-164.
Loizou S, Singh S, Wypkema E & Asherson RA. Anticardiolipin. Anti-β2- glycoprotein1 and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis 2003; 62: 1106-1111.
Asheron RA & Cervera R. Antipospholipid antibodies and infection. Ann Rheum Dis 2003; 26: 388-393.
Ali HA, Osman RR, Idris MN & Sokrab TO. Anticardiolipin antibodies in stroke patients in Sudan . Neurosciences 2007; Vol. 12 (1): 21-24.
Cervera R & Asherson RA. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics. Immunobiology 2005;210: 735–741.
Ordi-Ros J, Villarreal J, Monegal F, Sauleda S, Esteban I &Vilardell M. Anticardiolipin Antibodies in Patients with Chronic Hepatitis C Virus Infection: Characterization in Relation to Antiphospholipid Syndrome. Clin Diagn Lab Immunol. 2000 March; 7(2): 241–244.
Pybus OG, Drummond AJ, Nakano T, Robertson BH &Rambaut A. The Epidemiology and Iatrogenic Transmission of HCV in Egypt: A Bayesian Coalescent Approach. Mol Biol Evol 2003; 20 (3) : 381-7.
Global distribution of hepatitis A, B, and C. Weekly epidemiological record 2002;77 (6) :41-8.
Armstrong GL, Wasley A, Simard EP, Mcqillan G, Kuhnert WL & Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med.2006; 144: 705-14.
World Health Organization and Viral Hepatitis Prevention Board. Global surveillance and control of hepatitis C. J Viral Hepat. 1999; 6: 35-47.
Nguyen TT, Sedghi-Vaziri A & Wilkes LB. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat. 1996; 3:75-8.
Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002; 36:S35-46.
El-Zanaty F & Way A 2009. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International.
Lunel F& Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol, 1999; 31(Suppl.1): 210-6.
Trejo O, Ramos-Casals M & García-Carrasco M. Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001; 80:252–62.
Mohamed MK. Epidemiology of HCV in Egypt 2004. The Afro-Arab Liver Journal 2004; 3, (2):41-52.
Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HVC) infection and HVC-related chronic disease. Morbidity and Mortality Weekly Report. 2003; 47:1–39.
Raja NS& Janjua KA. Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect. J Microbiol Immunol Infect 2008, 41:4-8.
Berenguer M, Lopez-Labrador FX & Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001, 35:666-8.
De Francesco R, Tomei L, Altamura S, Summa V & Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 2003, 58:1-16.
Beaulieu PL, & Tsantrizos YS. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr Opin Investig Drugs 2004, 5:838-850.
Hope RG, Murphy DJ & McLauchlan J. The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins. J Biol Chem 2002, 277:4261-70.
Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA & Lemon SM. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterol 2002, 122:352-65.
Tellinghuisen TL & Rice CM. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol 2002, 5:419- 427.
Cappellini MD, Musallam KM, Marcon A & Taher AT. Coagulopathy in Beta Thalassemia Current Understanding Future Perspectives. Medit J Hemat Infect Dis 2009, 1(1):220090.
Tripodi A, Cappellini MD, Chantarangkul V, Padovan L, Fasulo MR, Marcon A & Mannucci PM. Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica 2009;94:1520-1527.